Xencor, Inc.
XNCRDrugs in Pipeline
4
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Dec 31, 2026
15wMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
How XNCR's past catalysts played out
XmAb5871
Systemic Lupus Erythematosus
vudalimab monotherapy
Metastatic Castration-Resistant Prostate Cancer
vudalimab
Ovarian Cancer
XmAb942
Ulcerative Colitis (UC)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
XmAb5871 | Phase 2 | Systemic Lupus Erythematosus | - | - |
vudalimab monotherapy | Phase 2 | Metastatic Castration-Resistant Prostate Cancer | - | - |
vudalimab | Phase 2 | Ovarian Cancer | - | - |
XmAb942 | Phase 2 | Ulcerative Colitis (UC) | - | - |
Systemic Lupus Erythematosus
1 drug in this indication
Ovarian Cancer
1 drug in this indication
Metastatic Castration-Resistant Prostate Cancer
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Xencor, Inc.'s drug pipeline?→
CatalystAlert tracks 4 drug candidates in Xencor, Inc.'s (XNCR) pipeline across Phase 2. Its lead program is XmAb5871 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Xencor, Inc.'s next FDA catalyst?→
Xencor, Inc.'s (XNCR) next tracked catalyst is a Data Readout expected December 31, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track XNCR biotech catalysts?→
Add XNCR to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Xencor, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.